CompletedNot Applicable

Clinical Characteristics, Treatment Patterns, and Outcomes of Hospitalized Patients With Refractory Inflammatory Bowel Disease

China1,048 participantsStarted 2020-01-01

Plain-language summary

the investigators conducted a multicenter retrospective cohort study of hospitalized patients with IBD from three tertiary referral centers in China to characterize the clinical features, treatment patterns, and outcomes of refractory IBD and to identify factors associated with refractory disease.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eligible patients had an established diagnosis of CD or UC based on clinical, endoscopic, radiologic, and histopathologic findings in accordance with European Crohn's and Colitis Organization guidance Exclusion Criteria: * Patients were excluded if they had participated in clinical trials or received investigational drugs, had concomitant malignancy, severe immunodeficiency, or other systemic autoimmune diseases, or were diagnosed with IBD-unclassified

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of Participants Achieving Clinical Remission as Assessed by CDAI or Partial Mayo Score at 12 Months

Timeframe: 1 year

Percentage of Participants Achieving Endoscopic Remission as Assessed by SES-CD, Rutgeerts Score, or Mayo Endoscopic Subscore at 12 Months

Timeframe: 1 year

Percentage of Participants Undergoing IBD-related Surgery Within 12 Months After the Most Recent Treatment Adjustment

Timeframe: 1 year

Trial details

NCT IDNCT07697521

SponsorShanghai 10th People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Inflamatory Bowel Disease trials

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Percentage of Participants Achieving Clinical Remission as Assessed by CDAI or Partial Mayo Score at 12 Months

Timeframe: 1 year

Percentage of Participants Achieving Endoscopic Remission as Assessed by SES-CD, Rutgeerts Score, or Mayo Endoscopic Subscore at 12 Months

Timeframe: 1 year

Percentage of Participants Undergoing IBD-related Surgery Within 12 Months After the Most Recent Treatment Adjustment

Timeframe: 1 year